MESO
Mesoblast·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MESO
Mesoblast Limited
A global leader in allogeneic cellular medicines for inflammatory diseases
Biological Technology
06/08/2004
11/13/2015
NASDAQ Stock Exchange
81
06-30
Depository Receipts (Ordinary Shares)
Level 38, 55 Collins Street, Melbourne , VIC, 3000, Australia
A biotechnology company in the field of adult stem cell technology
Mesoblast Limited was established in Australia on June 8, 2004. The company is a world leader in the development of allogeneic cell drugs. The company has built a broad portfolio of commercial and late-stage product candidates utilizing its proprietary mesenchymal spectrum cell therapy technology platform.
Company Financials
EPS
MESO has released its 2023 Q4 earnings. EPS was reported at -0.14, versus the expected -0.15, beating expectations. The chart below visualizes how MESO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MESO has released its 2023 Q4 earnings report, with revenue of 2.14M, reflecting a YoY change of -3.82%, and net profit of -21.92M, showing a YoY change of -2.16%. The Sankey diagram below clearly presents MESO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
